宁波三星医疗电气股份有限公司独立董事 独立董事：王溪红、段逸超、杨华军 2023年9月8日 一、关于部分募投项目完工并将结余募集资金永久性补充流动资金的议案 公司本次募投项目投入的设施已完工并达到可使用状态，能正常运营产生经 济效益。本次公司将结余募集资金永久性补充流动资金，有利于提高募集资金使 用效率，节约财务费用，有利于增强公司盈利能力。相关审议程序符合《上海证 券交易所上市公司自律监管指引第1号——规范运作》等相关法律法规和《宁波 三星医疗电气股份有限公司募集资金管理制度》的规定，未损害公司、股东特别 是中小股东的利益。我们同意公司募投项目完工并将结余募集资金永久性补充流 动资金。 关于第六届董事会第四次会议相关事项的独立意见 根据《上市公司治理准则》、《上市公司独立董事管理办法》、《上海证券 交易所上市公司自律监管指引第1号——规范运作》和《宁波三星医疗电气股份 有限公司章程》、《宁波三星医疗电气股份有限公司独立董事工作细则》的有关 规定，作为宁波三星医疗电气股份有限公司（以下简称"公司"）独立董事，我 们对公司第六届董事会第四次会议相关议案发表以下独立意见： ...

东方证券承销保荐有限公司关于 宁波三星医疗电气股份有限公司部分募投项目完工 并将结余募集资金永久性补充流动资金的核查意见 东方证券承销保荐有限公司（以下简称"东方投行"或"保荐机构"）作为 宁波三星医疗电气股份有限公司（以下简称"三星医疗"或"公司"）2016 年 非公开发行股票的保荐机构，根据《证券发行上市保荐业务管理办法》、《上市 公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求》、《上海证券 交易所上市公司募集资金管理办法（2013 年修订）》等有关规定，对三星医疗 本次完工募投项目并将结余募集资金永久性补充流动资金事项进行了专项核查， 核查具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会证监许可[2016]53 号文核准，2016 年 5 月公司 向特定对象非公开发行人民币普通股 220,102,714 股，发行价格为每股 13.63 元， 募集资金总额 2,999,999,991.82 元，扣除各项发行费用 34,713,487.58 元，实际募 集资金净额为 2,965,286,504.24 元，已于 2016 年 5 月 31 日全部到位，并已经立 信会计师事务所（特殊 ...

证券代码：601567 证券简称：三星医疗 公告编号：临 2023-078 一、审议通过了关于部分募投项目完工并将结余募集资金永久性补充流动资金的议 案 详见公司披露于上海证券交易所网站（www.sse.com.cn）的《三星医疗关于部分募 投项目完工并将结余募集资金永久性补充流动资金的公告》（公告编号：临 2023-080）。 表决结果：9 票赞成、0 票反对、0 票弃权。 独立董事对该议案发表了明确同意的意见，该议案尚需提交股东大会审议。 二、审议通过了关于召开 2023 年第三次临时股东大会的议案 详见公司披露于上海证券交易所网站（www.sse.com.cn）的《三星医疗关于召开 2023 年第三次临时股东大会的通知》（公告编号：临 2023-081）。 宁波三星医疗电气股份有限公司 第六届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁波三星医疗电气股份有限公司（以下简称"公司"）于2023年9月1日以电话、传 真、邮件等方式发出召开第六届董事会第四次会议的通知，会议于2023年9月8日在 ...

关于部分募投项目完工并将结余募集资金 永久性补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 宁波三星医疗电气股份有限公司（以下简称"公司"）于 2023 年 9 月 8 日召开第 六届董事会第四次会议，审议通过了《关于部分募投项目完工并将结余募集资金永 久性补充流动资金的议案》，同意公司将完工募投项目的结余募集资金 67,246.97 万 元用于永久性补充流动资金。独立董事、监事会、保荐机构就本次完工募投项目并 将结余募集资金永久性补充流动资金事项发表了明确同意意见，该事项尚需提交公 司股东大会审议。现将相关事宜公告如下： 证券代码：601567 证券简称：三星医疗 公告编号：临 2023-080 宁波三星医疗电气股份有限公司 一、募集资金基本情况 经中国证券监督管理委员会（以下简称"中国证监会"）《关于核准宁波三星医 疗电气股份有限公司非公开发行股票的批复》（证监许可[2016]53 号）核准，公司 本次实际非公开发行人民币普通股 220,102,714 股，发行价格为每股人民币 13.63 元， ...

宁波三星医疗电气股份有限公司 2023年第三次临时股东大会会议资料 二〇二三年九月二十七日 宁波三星医疗电气股份有限公司 2023年第三次临时股东大会会议资料 宁波三星医疗电气股份有限公司 2023年第三次临时股东大会会议资料目录 宁波三星医疗电气股份有限公司 2023年第三次临时股东大会会议资料 宁波三星医疗电气股份有限公司 2023 年第三次临时股东大会会议议程 时 间：2023 年 9 月 27 日（星期三）14:00 地 点：宁波市鄞州区首南街道日丽中路 757 号奥克斯中央大厦 25 楼会议室 主持人：沈国英董事长 2 议 程： 一、 主持人介绍到会股东、股东代表及代表股份数，宣布股东大会开始； 二、 推举计票人、监票人，发放表决票； 三、 审议股东大会议案： 1、 关于部分募投项目完工并将结余募集资金永久性补充流动资金的议案 四、 参会股东及股东代表发言或提问； 五、 现场参会股东及股东代表对议案进行投票表决； 六、 收集表决票并计票； 七、 宣布现场投票及网络投票合并后的表决结果； 八、 见证律师宣读本次股东大会法律意见书； 九、 宣读股东大会决议，签署会议决议等相关文件； 十、 股东大会闭幕。 ...

一、项目中标情况 宁波三星医疗电气股份有限公司（以下简称"公司"）于近日收到全资子公司宁 波奥克斯智能科技股份有限公司（以下简称"奥克斯智能科技"）在中国绿发投资集 团有限公司集中招标采购项目中中标的通知，奥克斯智能科技为风电及光伏项目预 装式变电站（华变）年度协议采购项目的中标人，中标总金额约为3.68亿元。 二、交易对方情况介绍 招标人：中国绿发投资集团有限公司 注册资本：4,499,607.64979万元人民币 证券代码：601567 证券简称：三星医疗 公告编号：临 2023-077 宁波三星医疗电气股份有限公司 关于经营合同中标的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中国绿发投资集团有限公司与公司不存在任何关联关系。 三、项目中标对公司的影响 本次奥克斯智能科技中标总金额约为3.68亿元，占公司2022年度经审计的营业总 收入的4.04%。合同的履行将对奥克斯智能科技2023年的经营工作和经营业绩产生积 极影响，但对公司业务、经营的独立性不产生影响。 四、风险提示 1、目前，公司已收到中标通知书，但尚 ...

宁波三星医疗电气股份有限公司（以下简称"公司"）于 2023 年 7 月 3 日 召开第六届董事会第二次会议审议通过了《关于全资子公司参与设立华文清能一 期股权投资（滁州）合伙企业（有限合伙）的议案》，公司同意全资子公司宁波 三星智能电气有限公司（以下简称"三星智能"）与华人文化（上海）股权投资 管理有限公司、安徽省三重一创产业发展二期基金有限公司、滁州市城投鑫创资 产管理有限公司、安徽辉隆农资集团股份有限公司、上海徽就企业管理咨询合伙 企业（有限合伙）共同投资设立华文清能一期股权投资（滁州）合伙企业（有限 合伙）（登记机关最终核准登记的名称为"华文清能一期投资基金（滁州）合伙 企业（有限合伙）"，以下简称"华文清能"）。基金总规模 100,000 万元，三 星智能出资 20,000 万元，占比 20%。具体内容详见公司于 2023 年 7 月 4 日披露 于上海证券交易所网站（www.sse.com.cn）、中国证券报、上海证券报和证券时 报的《三星医疗关于全资子公司参与设立华文清能一期股权投资（滁州）合伙企 业（有限合伙）的公告》（公告编号：临 2023-059）。 二、股权基金设立进展 2023 年 8 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached ¥5,548,815,114.66, representing a 26.17% increase compared to ¥4,397,991,777.64 in the same period last year[21]. - Net profit attributable to shareholders for the first half of 2023 was ¥869,708,954.73, a significant increase of 147.60% from ¥351,262,068.93 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was ¥815,965,505.34, up 66.29% from ¥490,696,624.18 year-on-year[21]. - The net cash flow from operating activities improved to ¥178,293,090.83, compared to a negative cash flow of ¥71,250,867.63 in the same period last year[21]. - The gross profit margin was 31.12%, an increase of 4.63 percentage points year-on-year, with net cash flow from operating activities of 178 million yuan, an increase of 250 million yuan year-on-year[59]. - The company reported a significant improvement in financial health, indicating a strong operational performance and effective management strategies[21]. Assets and Liabilities - The company's total assets increased by 6.98% to ¥17,360,211,841.59 from ¥16,227,718,923.75 at the end of the previous year[21]. - The net assets attributable to shareholders rose to ¥9,986,354,394.31, reflecting a 5.06% increase from ¥9,505,536,761.16 at the end of the last year[21]. - Total liabilities rose to CNY 7,258,591,810.92, compared to CNY 6,605,796,858.33, marking an increase of approximately 9.87%[171]. - The total current assets as of June 30, 2023, amounted to RMB 8,585,269,819.24, an increase from RMB 8,244,789,195.92 as of December 31, 2022, reflecting a growth of approximately 4.13%[169]. Market Position and Strategy - The company plans to continue expanding its market presence and invest in new product development to sustain growth[21]. - The company is positioned in the smart power distribution sector, benefiting from national policies promoting energy transition and digitalization[30]. - The company is actively responding to the Belt and Road Initiative, aiming to leverage overseas market opportunities in the global smart grid construction[30]. - The company aims to expand its rehabilitation hospital network, leveraging the benefits of chain operations in a fragmented industry[40]. - The company is focusing on expanding its non-grid market and enhancing its international brand influence, particularly in the renewable energy sector[96]. Research and Development - Research and development expenses rose by 43.86% to ¥210,022,708.01, reflecting the company's commitment to enhancing product competitiveness through increased investment in R&D[77]. - The company is actively involved in the development of artificial intelligence edge computing chips for applications in smart cities and smart energy[41]. - The company has established a rehabilitation medical research institute to promote the development of critical rehabilitation disciplines and enhance its academic influence[58]. Environmental Compliance - The company reported no administrative penalties related to environmental issues during the reporting period, indicating compliance with environmental regulations[119]. - The company generated 5,431 tons of CO2 equivalent reductions through various carbon reduction measures during the reporting period[120]. - The company completed the environmental monitoring plan in accordance with national guidelines, ensuring compliance with pollutant discharge standards[117]. Social Responsibility - The company has committed to invest CNY 100,000 annually from 2021 to 2025 to support economic development in Yuxi County, Sichuan, as part of its poverty alleviation efforts[128]. - The company is actively involved in social responsibility initiatives, including job creation for local farmers in supported regions[128]. - The company continues to focus on rural revitalization and poverty alleviation as part of its long-term strategic goals[128]. Shareholder and Governance - The board of directors confirmed the authenticity and completeness of the semi-annual report[7]. - The company has undergone a board and supervisory committee election, with new appointments made for key positions[106]. - The company reported no major litigation or arbitration matters during the reporting period, indicating a stable legal standing[140]. Acquisitions and Investments - The company completed the acquisition of multiple hospitals, including 100% stakes in several rehabilitation and general hospitals[103]. - The company plans to acquire 100% equity of Huzhou Zhebei Mingzhou Hospital for a total investment of RMB 224 million[143]. - The company has established partnerships with multiple investment entities to ensure compliance with profit commitments and social responsibilities[131].

证券代码：601567 证券简称：三星医疗 公告编号：临 2023-075 宁波三星医疗电气股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 宁波三星医疗电气股份有限公司（以下简称"公司"）已于 2023 年 8 月 24 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半年度经营成果、财务状况，公司计划于 2023 年 9 月 1 日下午 15:00-16:30 举 行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以视频结合网络互动召开，公司将针对 2023 年半年度经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （三）会议召开方式：上证路演中心视频直播和网络互动 三、参加人员 董事长：沈国英女士 总裁：易师伟先生 董事会秘书：郭粟女士 财务负责人：葛瑜斌先生 独立董事：段 ...

Financial Performance - The company's operating revenue for 2022 was CNY 9,098,202,561.40, representing a year-on-year increase of 29.55% compared to CNY 7,022,902,468.70 in 2021[17]. - The net profit attributable to shareholders of the listed company for 2022 was CNY 948,115,535.82, a 37.40% increase from CNY 690,042,564.52 in 2021[17]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 1,058,605,142.56, showing a significant increase of 103.90% compared to CNY 519,178,466.27 in 2021[17]. - The net cash flow from operating activities for 2022 was CNY 1,222,584,815.56, a remarkable increase of 514.54% from CNY 198,943,484.74 in 2021[17]. - The total assets at the end of 2022 were CNY 16,227,718,923.75, reflecting a year-on-year growth of 9.16% from CNY 14,865,322,029.25 in 2021[17]. - The net assets attributable to shareholders of the listed company at the end of 2022 were CNY 9,505,536,761.16, an increase of 7.13% compared to CNY 8,873,230,301.13 at the end of 2021[17]. - Basic earnings per share increased by 34.00% to CNY 0.67 in 2022 compared to CNY 0.50 in 2021[18]. - The weighted average return on equity rose to 10.32% in 2022, up 2.42 percentage points from 7.90% in 2021[18]. - The company reported a significant reduction in financial expenses, with a decrease of 116.82% to -¥14,852,529.09, attributed to increased exchange gains and reduced interest expenses[55]. Dividend Policy - The company plans to distribute a cash dividend of 3.50 RMB per 10 shares to all shareholders, totaling approximately 492.79 million RMB, which accounts for 51.98% of the net profit attributable to shareholders for the year[4]. - The company has not proposed any capital reserve transfer to increase share capital for the year[4]. - The cash dividend amount for 2022 represents 51.98% of the consolidated net profit attributable to ordinary shareholders[138]. - The cash dividend policy has been strictly executed since its amendment in 2013, ensuring compliance with regulations[137]. - The company confirmed that all decisions regarding dividends were made in accordance with the company's articles of association and shareholder resolutions[137]. Governance and Compliance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[4]. - The board of directors and supervisory board members have all attended the board meeting, ensuring the integrity of the annual report[4]. - There are no violations of decision-making procedures regarding external guarantees[5]. - The company has implemented a robust governance structure, ensuring compliance with legal and regulatory requirements while maintaining transparency in information disclosure[99]. - Independent directors fulfilled their responsibilities and ensured the protection of minority shareholders' rights[137]. Strategic Initiatives - The company is focused on expanding its market presence and enhancing its product offerings through new technology development[12]. - Future outlook includes strategic initiatives aimed at increasing operational efficiency and market share[12]. - The company plans to explore potential mergers and acquisitions to bolster its competitive position in the industry[12]. - The company is actively pursuing mergers and acquisitions to expand its market footprint and enhance service offerings[121]. - The company plans to continue expanding its market presence through strategic acquisitions and new product development initiatives[106]. Challenges and Risks - The company faced challenges due to global supply chain constraints and rising raw material costs in 2022[28]. - The company acknowledges investment risks associated with overseas acquisitions and the long payback period for new rehabilitation hospitals[96]. - The company is exposed to intense market competition in the medical services sector, which may adversely affect profitability if competitors enhance production and quality[95]. - The company relies heavily on domestic power system users for its smart distribution equipment, making it vulnerable to changes in national policies and investment scales[96]. Research and Development - Research and development expenses rose to ¥327,023,160.08, marking an 11.22% increase from ¥294,029,247.93[56]. - The company is focusing on capital increase for its subsidiary, Ningbo Aux High-Tech Co., Ltd., to support its growth initiatives[122]. - The company is committed to talent acquisition and training, establishing a partnership model with renowned medical teams to enhance its clinical capabilities[53]. Environmental Responsibility - The company achieved a total carbon dioxide equivalent reduction of 13,545 tons through various measures[161]. - The rooftop photovoltaic power generation project has a capacity of 12MW, resulting in an annual reduction of 13,272 tons of CO2 emissions[162]. - The company has implemented a self-monitoring plan for pollutant emissions, ensuring compliance with national environmental standards[157]. - The company processed 5.21 tons of hazardous waste (packaging barrels) and 7.51 tons of non-hazardous waste (waste activated carbon) through qualified third-party disposal[151]. Social Responsibility - The company has committed to invest 100,000 yuan annually from 2021 to 2025 to support economic development in the Yuxi County of Daliangshan, Sichuan, as part of its poverty alleviation efforts[166]. - A total of 553 individuals benefited from labor cooperation projects established in various regions, including Guizhou and Sichuan, from 2020 to 2022, addressing labor shortages while supporting poverty alleviation[167]. - The company has engaged in targeted poverty alleviation efforts, aligning with national initiatives to support rural revitalization and economic development[166]. Acquisitions and Investments - The company completed 100% equity acquisitions of five rehabilitation hospitals, enhancing its operational experience and scale effects in the medical service sector[32]. - The company approved the acquisition of 100% equity in multiple rehabilitation hospitals, including Nanjing Mingzhou Rehabilitation Hospital and Wuhan Mingzhou Rehabilitation Hospital, as part of its expansion strategy[106]. - The company has committed to significant acquisitions and expansions in the rehabilitation sector, enhancing its market presence[186].